Popular Articles

Apthera Receives Special Protocol Assessment (SPA) From FDA For Pivotal Phase III Trial Of NeuVax In Early-Stage Breast Cancer
Apthera, Inc. announced that it reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its planned Phase III clinical trial of the Company"s lead drug, NeuVax. The SPA is a written agreement between the trial"s sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of the Phase III trial to be used in support of a Biologics License Application (BLA).
generic viagra online
New Study Finds Social And Economic Factors Play Major Role In Determining Who Gets Bariatric Surgery
Less than one-half of one percent (0.4%) of the 22 million people in the U.S. who are medically eligible for bariatric surgery actually get the surgery, and those who do are most likely to be white females with higher incomes and covered by private health insurance, according to a new study presented here at the 26th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
News of the day
Deep Vein Thrombosis: The Risk During A Flight Is Often Overestimated
The risk of developing deep vein thrombosis during a long flight is often overestimated. According to the German Institute for Quality and Efficiency in Health Care (IQWiG), this condition is very unlikely in healthy travellers. When people wear a cast or splint after a sports accident, on the other hand, many are not aware that they have an increased risk of deep vein thrombosis in their leg and pelvic area. This is emphasised in information published on IQWiG"s website Informed Health Online.
Oncology

Ginkgo Reduces Neuropathic Pain In Animal Studies

An extract of ginkgo biloba shows scientific evidence of effectiveness against one common and hard-to-treat type of pain, according to animal data reported in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS). Dr. Yee Suk Kim and colleagues of The Catholic University of Seoul, South Korea, performed experiments in rats to evaluate the effectiveness of ginkgo against neuropathic pain, a common pain problem associated with herpes zoster, limb injury, or diabetes. Affected patients may feel severe pain in response to harmless stimuli like heat, cold, or touch. Objective Evidence of Pain Reduction with Ginkgo In the experiments, rats with neuropathic pain were treated with different doses of a standardized ginkgo biloba extract or with an inactive solution. Objective tests were performed to see how ginkgo affected neuropathic pain responses to cold and pressure. For both cold and pressure stimuli, pain responses were significantly reduced in ginkgo-treated rats. This was so on before-and-after treatment comparisons and on comparison of ginkgo-treated versus placebo-treated animals. The higher the dose of ginkgo extract, the greater the pain-relieving effect. Pain was reduced for at least two hours after ginkgo treatment. The study provides no evidence as to how ginkgo works to reduce pain. Several mechanisms are possible, including antioxidant activity, an anti-inflammatory effect, or protection against nerve injur perhaps in combination. Many herbs and "alternative" drugs are commonly used without prescriptions for a wide range of purposes, despite a lack of scientific evidence for health claims. Ginkgo, one of the most popular herbal products, is widely used as a memory enhancer, among other purposes. The new study provides the first scientific evidence that ginkgo has a real effect in reducing neuropathic pain. New treatments are needed for neuropathic pain, which does not always respond well to available treatments. "It"s still too early to stock up on ginkgo biloba if you have chronic pain," comments Dr. Steven L. Shafer of Columbia University, Editor-in-Chief of Anesthesia & Analgesia. Many treatments that are effective in animals do not prove to be effective in humans, or prove to have unacceptable toxic effects when given to patients, Dr. Shafer reminds. "However," he adds, "it is at least reassuring to know that scientists are investigating the properties of this ancient oriental herbal medication in an effort to determine what chemical constituents account for the many beneficial effects traditionally ascribed to it." About the IARS The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to encourage, stimulate, and fund ongoing anesthesia-related research and projects that will enhance and advance the anesthesiology specialty. The IARS has a worldwide membership of 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia-related practice. In additional to publishing the monthly scientific journal Anesthesia & Analgesia, the IARS sponsors an annual clinical and scientific meeting, funds anesthesia-related research, and sponsors the Global Perioperative Research Organization (GPRO). About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.About Lippincott Williams & Wilkins IARS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):